抗IL-1 Receptor Antagonist抗体(Anti-IL-1 Receptor Antagonist, Mouse, Goat-Poly antibody)

• 価格
• Product Details
• Applications and Data
• Data Examples
• Related Research Areas
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Mouse
Label	Unconjugated
Immunogen	E. coli-derived recombinant mouse IL‑1ra/IL-1F3
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Specificity	Detects mouse IL-1ra/IL-1F3 in ELISAs and Western blots. In sandwich ELISAs, approximately 45% cross-reactivity with recombinant rat IL‑1ra/IL‑1F3 and less than 1% cross-reactivity with recombinant human IL‑1ra/IL‑1F3, recombinant porcine IL‑1ra/IL‑1F3, and recombinant equine IL‑1ra/IL‑1F3 is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Mouse IL‑1ra/IL‑1F3 (Catalog # 480-RM)
Mouse IL-1ra/IL-1F3 Sandwich Immunoassay	Reagent
ELISA Capture (Matched Antibody Pair)	0.2-0.8 µg/mL	Mouse IL‑1ra/IL‑1F3 Antibody (Catalog #AF-480-NA )
ELISA Detection (Matched Antibody Pair)	0.1-0.4 µg/mL	Mouse IL‑1ra/IL‑1F3 Biotinylated Antibody (Catalog #BAF480 )
ELISA Standard		Recombinant Mouse IL-1ra/IL-1F3 Protein (Catalog #480-RM )
Neutralization	Measured by its ability to neutralize IL‑1ra/IL‑1F3 inhibition of IL‑1 alpha /IL‑1F1-dependent proliferation in the D10.G4.1 mouse helper T cell line [Symons, J.A. et al. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 272]. The Neutralization Dose (ND50) is typically 1-5 µg/mL in the presence of 150 ng/mL Recombinant Mouse IL‑1ra/IL‑1F3, 50 pg/mL Recombinant Human IL‑1 alpha /IL‑1F1 and 1.25 µg/mL concanavalin A.
Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website.

目次に戻る

Data Examples

Neutralization	click image to view larger	IL‑1ra/IL‑1F3 Inhibition of IL‑1 alpha /IL‑1F1-dependent Cell Proliferation and Neutralization by Mouse IL‑1ra/IL‑1F3 Antibody.Recombinant Mouse IL‑1ra/IL‑1F3 (Catalog # 480‑RM) inhibits Recombinant Human IL‑1 alpha /IL‑1F1 (Catalog # 200‑LA) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL‑1 alpha /IL‑1F1 (50 pg/mL) activity elicited by Recombinant Mouse IL‑1ra/IL‑1F3 (150 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL‑1ra/IL‑1F3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-480-NA). The ND50 is typically 1-5 µg/mL in the presence of concanavalin A (1.25 µg/mL).
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.	Reconstitution Buffer Available
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-1ra/IL-1F3	IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally-occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha. It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells. In mouse, IL-1 RII does not bind IL-1ra. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Pre-clinical and clinical studies were done to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.
Long Name:	Interleukin 1 Receptor Antagonist
Entrez Gene IDs:	3557 (Human); 16181 (Mouse); 60582 (Rat); 397499 (Porcine)
Alternate Names:	DIRA; ICIL-1RA; IL1F3; IL-1F3; IL1ra; IL-1ra; IL-1ra3; IL1RN; IL-1RN; interleukin 1 receptor antagonist; IRAP; MVCD4

目次に戻る

Related Research Areas

Cytokine and Growth Factor Receptors on VSMC

Cytokines and Receptors in Allergy and Asthma

Cytokines and Receptors in Angiogenesis

IL-1 Family

Macrophage Activation Markers

Neuroinflammation

Effective combinatorial immunotherapy for castration-resistant prostate cancer Authors: X Lu, JW Horner, E Paul, X Shang, P Troncoso, P Deng, S Jiang, Q Chang, DJ Spring, P Sharma, JA Zebala, DY Maeda, YA Wang, RA DePinho Nature, 2017;543(7647):728-732. Species: Mouse Sample Type: Whole Cells Application: Neut

Neutralization

IL‑1ra/IL‑1F3 Inhibition of IL‑1 alpha /IL‑1F1-dependent Cell Proliferation and Neutralization by Mouse IL‑1ra/IL‑1F3 Antibody. Recombinant Mouse IL‑1ra/IL‑1F3 (Catalog # 480‑RM) inhibits Recombinant Human IL‑1 alpha /IL‑1F1 (Catalog # 200‑LA) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL‑1 alpha /IL‑1F1 (50 pg/mL) activity elicited by Recombinant Mouse IL‑1ra/IL‑1F3 (150 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL‑1ra/IL‑1F3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-480-NA). The ND50 is typically 1-5 µg/mL in the presence of concanavalin A (1.25 µg/mL).

目次に戻る

Related Product & Information

Long Name	Interleukin 1 Receptor Antagonist
Entrez Gene IDs	3557 (Human); 16181 (Mouse); 60582 (Rat); 397499 (Porcine)
Background	IL-1ra/IL-1F3
background_content	Background: IL-1ra/IL-1F3 IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally-occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha. It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells. In mouse, IL-1 RII does not bind IL-1ra. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Pre-clinical and clinical studies were done to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.

目次に戻る

Citations

1. Effective combinatorial immunotherapy for castration-resistant prostate cancer
   Authors: X Lu, JW Horner, E Paul, X Shang, P Troncoso, P Deng, S Jiang, Q Chang, DJ Spring, P Sharma, JA Zebala, DY Maeda, YA Wang, RA DePinho
   Nature, 2017;543(7647):728-732.
   Species: Mouse
   Sample Type: Whole Cells
   Application: Neut


2. Correction: Yersinia pestis Activates Both IL-1beta and IL-1 Receptor Antagonist to Modulate Lung Inflammation during Pneumonic Plague.
   PLoS Pathog, 2015;11(5):e1004921.
   Species: Mouse
   Sample Type: In Vivo
   


3. Brain interleukin-1beta and the intrinsic receptor antagonist control peripheral Toll-like receptor 3-mediated suppression of spontaneous activity in rats.
   Authors: Yamato M, Tamura Y, Eguchi A, Kume S, Miyashige Y, Nakano M, Watanabe Y, Kataoka Y
   PLoS ONE, 2014;9(3):e90950.
   Species: Rat
   Sample Type: In Vivo
   Application: Neut


4. Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.
   Authors: Osuchowski MF, Connett J, Welch K, Granger J, Remick DG
   Crit. Care Med., 2009;37(5):1567-73.
   Species: Mouse
   Sample Type: Plasma
   Application: ELISA Development


5. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury.
   Authors: Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG
   Proc. Natl. Acad. Sci. U.S.A., 2007;104(26):11002-7.
   Species: Mouse
   Sample Type: Whole Cells
   Application: Neut


6. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality.
   Authors: Osuchowski MF, Welch K, Siddiqui J, Remick DG
   J. Immunol., 2006;177(3):1967-74.
   Species: Mouse
   Sample Type: Plasma
   Application: ELISA Development


7. Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression.
   Authors: Park EM, Cho BP, Volpe BT, Cruz MO, Joh TH, Cho S
   Neuroscience, 2005;132(3):625-31.
   Species: Rat
   Sample Type: Whole Cells
   Application: Neut


8. Sequential ELISA to profile multiple cytokines from small volumes.
   Authors: Osuchowski MF, Siddiqui J, Copeland S, Remick DG
   J. Immunol. Methods, 2005;302(1):172-81.
   Species: Mouse
   Sample Type: Plasma
   Application: ELISA Development

目次に戻る